Study Summary
CD19-directed CAR-T cell therapy has shown promising results for the treatment of relapsed or refractory B-cell malignancies; however, a subset of patients relapse due to the loss of CD19 in tumor cells. Dual Specificity CD19 and CD20 or CD22 CAR-T cells can recognize and kill the CD19 negative malignant cells through recognition of CD20 or CD22. This is a phase 1/2 study designed to determine the safety of the allogenic gene-edited dual specificity CD19 and CD20 or CD22 CAR-T cells and the feasibility of making enough to treat patients with relapsed or refractory hematological malignancies.
Want to learn more about this trial?
Request More InfoInterventions
Universal Dual Specificity CD19 and CD20 or CD22 CAR-T CellsBIOLOGICAL
1. Biological: Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells
2. Day 0: 10% of total dose Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose. D2: 60% of total dose if patient is stable (no significant toxicity) from prior dose
3. Other: Laboratory Biomarker Analysis
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Biotherapeutic Department and Hematology Department of Chinese PLA General Hospital | Beijing | Beijing Municipality | China |